XTL Biopharm SP (XTLB) Swings to Q3 Loss

XTL Biopharm SP (Nasdaq: XTLB) reported Q3 EPS of $-0.00, versus $0.00 reported last year. Revenue was $287 thousand, versus $473 thousand posted in Q313.

For earnings history and earnings-related data on XTL Biopharm SP (XTLB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Diana Shipping drops bid for Genco after price demands spike to $36.91